- Revenues to September 30, 2017: +7%
- Continuing strong growth in theranostics sales: +27%
- Percentage of revenues from internal products maintained: 74%
Croissy-Beaubourg and Montpellier, October 26, 2017, 6:00pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in vitro diagnostics and theranostics, today reported its consolidated revenues at the end of September 2017.
|In thousands of euros||September 30, 2017||September 30, 2016||Change|
|o/w Lisa Tracker® revenues||3,144||2,484||+27%|
|o/w IVD revenues||3,693||3,896||-5%|
During the period to September 30, 2017, Theradiag generated consolidated revenues of €6.8 million, up +7% compared with 2016.
Growth was driven by the Theranostics business unit and strong revenue growth for the Lisa Tracker® (+27% compared with the period to September 30, 2016).
Export revenues totalled €3.6 million, representing 52% of total revenues.
Up +11% in Q3 2017 compared to the same quarter of 2016, IVD revenues decreased only by 5% compared to the same period of last year. This was achieved despite the lack of growth drivers to be generated by the launch of BioCLIA, which has not yet taken place.
Michel Finance, Theradiag’s Chief Executive Officer, comments: “During the third quarter, further growth in Theranostics revenues, relating to partnerships with pharmaceuticals companies and the development of sales in the United States, as well as lower operating expenses, support our aim of reaching breakeven in 2018.”
Negotiations with our Chinese partner HOB Biotech have been pursued actively over the last few weeks.
Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag is developing new biomarkers based on microRNAs for the diagnosis and monitoring of rectal cancer, auto-immune and inflammatory diseases and HIV/AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has over 70 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
Tel.: +33 (0)1 64 62 10 12
& Investor Relations
Tel.: +33 (0)1 44 71 94 94
Tel.: +33 (0)1 44 54 36 64